Treatment for Positive QuantiFERON TB Gold Test with Negative Chest X-ray

Diagnosis Confirmation

A positive QuantiFERON TB Gold test indicates infection with Mycobacterium tuberculosis, but does not distinguish between active TB disease and LTBI, according to the Centers for Disease Control and Prevention 2
Negative chest X-ray helps rule out active TB disease, suggesting latent infection, as recommended by the Centers for Disease Control and Prevention 2
Additional evaluation should be performed to definitively exclude active TB, including clinical assessment for TB symptoms and sputum examination if clinically indicated, as suggested by the American Thoracic Society 1

9 months of isoniazid (INH) is the recommended regimen for LTBI in patients with radiographic evidence of prior TB and negative sputum cultures, according to the American Thoracic Society 1
This regimen has demonstrated significant reduction in progression to active TB in patients with fibrotic lesions, as reported by the American Thoracic Society 1
4 months of rifampin (RIF) with or without INH can be considered for patients who cannot tolerate 9 months of INH, as recommended by the American Thoracic Society 1
2 months of rifampin and pyrazinamide (RIF-PZA) can be considered for patients unlikely to complete longer courses, but requires careful monitoring due to risk of hepatotoxicity, as suggested by the American Thoracic Society 1

Baseline liver function tests should be performed before starting treatment, as recommended by the American Academy of Dermatology 3
Monthly clinical evaluation for medication side effects and adherence is necessary, according to the Centers for Disease Control and Prevention 2
Patient education regarding symptoms of hepatitis is crucial, as suggested by the Centers for Disease Control and Prevention 2
Liver function tests should be monitored in patients with baseline abnormalities, risk factors for hepatotoxicity, or symptoms suggesting hepatotoxicity, as recommended by the American Academy of Dermatology 3

The risk of progression to active TB is higher in persons with recent infection, abnormal chest radiograph consistent with prior TB, or immunosuppression, as reported by the American Thoracic Society 1 and the Centers for Disease Control and Prevention 2
Screening and treatment for LTBI is particularly important for patients who will undergo treatment with TNF-α antagonists, according to the Centers for Disease Control and Prevention 2
Annual chest X-ray may be considered at the discretion of the treating physician for high-risk individuals, as suggested by the American Academy of Dermatology 4
No routine follow-up testing with QuantiFERON is recommended after treatment, as the test may remain positive even after successful treatment of LTBI, according to the American Academy of Dermatology 5